Valuation: Kane Biotech Inc

Market Cap 6.15M 4.4M 3.93M 3.63M 3.29M 418M 6.25M 43.66M 17.29M 219M 16.51M 16.16M 690M P/E 2024
2.42x
P/E 2025 -2x
Enterprise Value 7.55M 5.4M 4.82M 4.46M 4.04M 513M 7.68M 53.62M 21.23M 269M 20.27M 19.84M 847M EV / Sales 2024
8.14x
EV / Sales 2025 20.3x
Free-Float
60.18%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 61 2025-05-01
Director of Finance/CFO - 2017-09-04
Chief Tech/Sci/R&D Officer 75 2022-04-04
Director TitleAgeSince
Chairman - 2025-05-31
Director/Board Member - 2023-11-15
Chairman 61 2024-02-19
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 635B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.09%+2.17%+37.02%+69.16% 444.85B
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2024 2025
Net sales 2.08M 1.49M 1.33M 1.23M 1.11M 141M 2.12M 14.77M 5.85M 74M 5.58M 5.46M 233M 428K 306K 273K 252K 229K 29.04M 435K 3.04M 1.2M 15.22M 1.15M 1.12M 47.97M
Net income 6.1M 4.36M 3.89M 3.6M 3.26M 414M 6.2M 43.28M 17.14M 217M 16.36M 16.01M 684M -2.72M -1.95M -1.74M -1.61M -1.45M -185M -2.77M -19.31M -7.65M -96.77M -7.3M -7.15M -305M
Net Debt 1.82M 1.3M 1.16M 1.07M 971K 123M 1.85M 12.89M 5.1M 64.59M 4.87M 4.77M 204M 1.4M 1M 896K 827K 750K 95.2M 1.43M 9.96M 3.94M 49.88M 3.76M 3.68M 157M
Logo Kane Biotech Inc
Kane Biotech Inc. is a Canada-based biotechnology company, which is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company’s segments include Animal health, and Human health. It has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The Company's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
Employees
-